Clinical Trial Update: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 trial of sorafenib for patients with recurrent or metastatic head and neck cancer and indicates the study status a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasopharyngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Salivary Gland Cancer
• Tongue Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED